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Abstract 
 
Background: Serum anti-heart autoantibodies (AHA) and anti-intercalated disk autoantibodies 
(AIDA) are autoimmune markers in myocarditis. In arrhythmogenic right ventricular 
cardiomyopathy (ARVC) myocarditis has been reported. To provide evidence for autoimmunity, 
we searched for AHA and AIDA in ARVC.  
Methods:  We studied: 42 ARVC probands, 23 male, aged 42, interquartile range (IQR) 33;49, 
20 from familial and 22 non-familial pedigrees; 37 clinically affected relatives (AR), 24 male 
aged 35, IQR 18;46; 96 healthy relatives (HR), 49 male, aged 27, IQR 17;45. Serum AHA and 
AIDA were tested by indirect immunofluorescence on human myocardium and skeletal muscle 
in 171 of the 175 ARVC individuals and in controls with: non-inflammatory cardiac disease 
(NICD) (n=160), ischemic heart failure (IHF) (n=141), normal blood donors (NBD) (n=270).  
Screening of five desmosomal genes was performed in probands; when a sequence variant was 
identified, cascade family screening followed, blind to immunological results.  
Results: AHA frequency was higher (36.8%) in probands, AR (37.8%) and HR (25%) than in 
NICD (1%), IHF (1%) or NBD (2.5%) (p=0.0001). AIDA frequency was higher in probands 
(8%, p=0.006), in AR (21.6%, p=0.00001) and in HR (14.6% p=0.00001) than in NICD (3.75%), 
IHF (2%) or NBD (0.3%). AHA positive status was associated with higher frequency of 
palpitation (p=0.004), ICD implantation (p=0.021), lower left ventricular ejection fraction 
(LVEF) (p=0.004), AIDA positive status with both lower RV and LVEF (p=0.027 and p=0.027 
respectively). AHA and/or AIDA positive status in the proband and/or at least one of the 
respective relatives was more common in familial (17/20, 85%) than in sporadic (10/22, 45%) 
pedigrees (p=0.007). 
Conclusions: Presence of AHA and AIDA provides evidence of autoimmunity in the majority of 
familial and in almost half of sporadic ARVC. In probands and in AR these antibodies were 
associated with disease severity features; longitudinal studies are needed to clarify whether they 
may predict ARVC development in HR or if they be a result of manifest ARVC. 
 
Key Words: arrhythmogenic right ventricular cardiomyopathy; autoimmunity; autoantibodies 
 
Nonstandard Abbreviations and Acronyms 
AHA:  anti-heart autoantibodies 
AIDA: anti-intercalated disk autoantibodies  
AR: affected relatives 
ARVC: arrhythmogenic right ventricular cardiomyopathy 
DSC2: desmocollin-2 
DSG2: desmoglein-2  
DSP: desmoplakin 
EF: ejection fraction 
EMB: endomyocardial biopsy 
PKP2: plakophilin-2 
HR: healthy relatives  
JUP: plakoglobin 
IF: indirect immunofluorescence 
IHF:  ischemic heart failure  
LVEF: left ventricular ejection fraction 
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NBD: normal blood donors 
NICD: non-inflammatory cardiac disease 
RV: right ventricular 
 
Clinical Perspective 
 
What is new? 
• This is the first family study reporting an increased frequency of serum organ-specific 
anti-heart autoantibodies (AHA) and anti-intercalated disk autoantibodies (AIDA) in a 
sizable arrhythmogenic right ventricular cardiomyopathy (ARVC) cohort of patients and 
relatives as compared to controls, in keeping with autoimmune involvement.  
• Positive AHA status was associated with lower left ventricular ejection fraction (LVEF), 
higher frequency of cardiac symptoms and implantable cardioverter defibrillator 
implantation, positive AIDA with lower biventricular ejection fraction (EF). 
• Another unique finding is that AHA and/or AIDA positive status was more common in 
familial than in sporadic pedigrees. 
 
What are the clinical implications? 
• Presence of organ-specific AHA and AIDA provides evidence of autoimmunity in the 
majority (85%) of familial and in almost half (45%) of sporadic ARVC. In probands and 
in affected relatives these antibodies were associated with disease severity features. 
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Introduction 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a significant cause of sudden 
cardiac death in the young. It is considered a genetically determined heart muscle disease of the 
desmosome, characterized by progressive fibrous or fibro-fatty replacement of the myocardium 
and ventricular arrhythmias,1–9 although non-desmosome genetic causes and sporadic disease 
may occur.1–11 Virus-negative myocarditis is reported in a high proportion of histologically-
proven ARVC, but its pathogenic significance remains elusive.12–14 
ARVC is a complex diagnosis, requiring fulfillment of a set of clinical, pathological and genetic 
criteria, first proposed in 19942 and revised in 2010 by an international expert Task Force3. In the 
early stages, ARVC may present with “hot phases” of chest pain, palpitations, and release of 
troponins, closely resembling clinically suspected myocarditis with pseudo-infarct 
presentation.12,14 The myocarditis phenotype in the early stages of disease onset has been clearly 
documented also in transgenic animal models of ARVC.15 Virus-negative myocarditis is often an 
autoimmune disease16 in which organ-specific and disease-specific serum anti-heart 
autoantibodies (AHA) and anti-intercalated disk autoantibodies (AIDA) represent reliable 
autoimmune biomarkers in affected patients (with or without ventricular dysfunction and 
regardless of the clinical presentation) as well as in their apparently healthy relatives at risk of 
disease development. 17-21 A recent study, on 45 index ARVC patients and a limited number of 
normal and non ARVC cardiomyopathy sera, reported an anti-desmoglein-2 (DSG-2) antibody to 
be associated with ARVC; relatives were not studied. 22 To provide evidence for autoimmunity 
from family studies, this study aimed at assessing prevalence, clinical and genetic correlates of 
AHA and AIDA in a sizable single centre cohort of ARVC probands, affected (AR) and healthy 
relatives (HR) as compared to a large number of normal and non ARVC cardiomyopathy sera. 
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Methods 
Study patients 
The study groups included 175 individuals (42 ARVC probands, of whom 20 from familial and 
22 from sporadic pedigrees, 37 AR fulfilling the 2010 revised Task force diagnostic criteria3 and 
96 HR followed at the Cardiomyopathy Unit, San Camillo Hospital, Rome, Italy) (Figure 1). 
Familial disease was defined as at least 1 AR besides the proband, sporadic as no AR besides the 
proband; 117 relatives were from familial and 16 from sporadic pedigrees.  The study protocol 
followed the ethical guidelines of the Declaration of Helsinki, obtained Institutional Review 
Board approval at S. Camillo Hospital and all participants gave written informed consent. In 
keeping with the 2010 revised diagnostic Task force criteria,3 individuals underwent standard 12-
lead ECG, signal-averaged ECG, 24 -hour Holter monitoring, echocardiography, and 
cardiovascular magnetic resonance imaging (CMR). Probands and AR underwent complete 
cardiac catherization and endomyocardial biopsy (EMB) when clinically indicated to reach 
diagnosis. 
Serum AHA and AIDA testing by indirect immunofluorescence (IF) 
The data, analytic methods, and study materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the procedure because of lack of diagnostic 
sera after testing for the present study. AHA and AIDA were detected by indirect 
immunofluorescence (IF) at 1/10 dilution on 4 µm-thick unfixed fresh frozen cryostat sections of 
blood group O normal human atrium and skeletal muscle.19-21  Two sera were used as standard 
positive and negative controls and titrated in every assay. All sera were read blindly against these 
standards using a fluorescence microscope (Zeiss Axioplan 2 imaging, Zeiss, New York). An 
additional positive control serum was titrated to assess reproducibility. End point titres for this 
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serum were reproducible within one double dilution in all assays.17,19-21  The frequency of AHA 
and of AIDA in ARVC was compared with that observed in previously established control 
groups of non-inflammatory heart disease (NICD) (n=160, 80 male, aged 37±17 years, of whom 
n=55 rheumatic heart disease, n = 67 hypertrophic cardiomyopathy, and n= 38 congenital 
defects), ischemic heart disease (n=141, 131 male, aged 44±14 years) and normal individuals 
(n=270, 123 male, age 35±11). 17,19-21   These control sera were obtained with informed consent 
from patients admitted to hospital and tested blindly from diagnosis at the time of description 
and validation of the IF assay. 17,19-21  
Genetic testing 
Genetic screening of five desmosomal genes associated with ARVC was performed on 38 of the 
42 ARVC index cases (Figure 1). When a sequence variant was identified in an index case, 
cascade screening followed in the corresponding families. In all cases, genetic screening was 
carried out blind to the immunological test results. In total, genomic DNA from 139 of the 175 
index patients and family members was extracted from whole blood with QIAamp DNA Blood 
mini kits (Qiagen). Primer pairs were designed to amplify the coding exons and the flanking 
intronic sequences of five ARVC related desmosomal genes: plakophilin-2 (PKP2), desmoplakin 
(DSP), desmocollin-2 (DSC2), desmoglein-2 (DSG2) and plakoglobin (JUP). PCR amplification 
was carried out using standard protocols (AmpliTaq Gold, Applied Biosystems) for all fragments 
except those with high GC content which were amplified with the GC RICH PCR system 
(Roche), as previously described.5,6,23 After amplification, PCR fragments were sequenced in 
both directions on an ABI PRISM 3130 DNA analyzer using BigDye Terminator chemistry 
(version 3.1) and analyzed by Seqscape version 2.0 software (Applied Biosystems). Sequence 
variants detected in ARVC patients were cross referenced to the updated version of the ARVD/C 
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Genetic Variants Database (https://molgenis07.gcc.rug.nl/# - accessed on 25 Sep 2018).24 The 
minor allele frequency of each variant on the Genome Aggregation Database (gnomAD) was 
determined using the gnomad browser (http://gnomad.broadinstitute.org/ - gnomAD r2.0.2 - 
accessed on 25 Sep 2018). Classification of identified variants was based on the American 
College of Medical Genetics (ACMG) guidelines for the interpretation of sequence variants 25.  
In particular, missense variants were evaluated using the InterVar bioinformatics software tool 
(http://wintervar.wglab.org/) 26 whilst the pathogenicity of nonsense and frameshift variants was 
determined with the online Genetic Variant Interpretation Tool provided by the University of 
Maryland, School of Medicine at 
http://www.medschool.umaryland.edu/Genetic_Variant_Interpretation_Tool1.html/ 27.  
Statistical analysis 
Results for quantitative measures are given as meanSD or as median (interquartile range) for 
variables deviating from normal distribution, qualitative measures are given as frequency 
(percentage). Quantitative variables were compared by one-way analysis of variance, Student’s t-
test, if normally distributed, or by Mann-Whitney test if deviating from normal distribution. 
Qualitative measures were compared by 2 test or Fisher’s exact test as appropriate.  
To account for clustering of observations in families a random effect model was implemented for 
each variable of interest also including family size in the model. Random effect model was in the 
class of the Generalised Linear Mixed Models fitted using Markov chain Monte Carlo 
techniques28. 
Given the high number of statistical tests performed, all p-values were adjusted for 
multiplicity to control the false discovery rate (i.e.: the expected proportion of false discoveries 
amongst the rejected hypotheses) to keep power also in presence of test dependence 29 . Adjusted 
 
D
ow
nloaded from
 http://ahajournals.org by on A
pril 3, 2020
10.1161/CIRCULATIONAHA.119.043931 
8 
p-values less than 0.05 were considered to indicate statistical significance and explicitly reported 
if below 0.10, otherwise “ns” was stated. All descriptive statistical analyses were performed 
using the SPSS software version 25.0 (SPSS, Inc, Chicago, IL; 2017) and inferential evaluations 
were conducted using the R-System 30 and the MCMCglmm libraries 31. 
 
Results 
Baseline features in ARVC patients and relatives. 
The clinical and diagnostic features at baseline are given in Table 1. Briefly, probands compared 
to AR and HR were more symptomatic, had larger right ventricular (RV) dimensions and lower 
biventricular function, and a higher number of fulfilled revised Task Force diagnostic criteria. 
Ventricular arrhythmia burden on ECG and 24-hour ECG Holter monitoring was higher in 
probands; an implantable cardioverter defibrillator (ICD) was implanted in 11 (26%) of 
probands, in 1 (2.7%) AR and in none of the HR (p=0.007). All patients with an EMB sample of 
sufficient quality for unequivocal pathological diagnosis showed typical ARVC, none had 
histological or immunohistochemical evidence of myocarditis, but focal areas of inflammation 
might have not been sampled. Of interest, a family history for autoimmune disease was found in 
a sizable proportion of probands (38%) and AR (40.5%). 
AHA and AIDA: frequency and associations with clinical and diagnostic features.  
Sera from 171 (38 probands, 37 AR and 96 HR) out of the 175 ARVC probands and relatives, 
taken at baseline evaluation with informed consent, were collected and tested at the same time of 
genetic study (Figure 1) blindly from clinical diagnosis. Organ-specific and cross-reactive AHA 
patterns were classified as described; 19-21  representative examples are shown in Figure 2. 
Briefly, organ-specific AHA gave diffuse cytoplasmic with or without additional fine striational 
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staining of atrial myocytes, but were negative on skeletal muscle; cross-reactive 1 or partially 
organ-specific AHA gave a fine striational staining on atrium, and were negative or only weakly 
stained skeletal muscle; cross-reactive 2 AHA gave a broad striational pattern on longitudinal 
sections of heart and skeletal muscle. 19-21Absorption studies with relevant tissues had confirmed 
the organ-specificity and cross-reactivity of the AHA patterns.21 AIDA gave a linear staining of 
the intercalated disks between cardiac myocytes.20 The frequency of AHA was higher in ARVC 
probands (14/38, 36.8%, p=0.0001), AR (14/37, 37.8%, p=0.0001) and HR (24/96, 25%, 
p=0.0001) than in NICD (2/160, 1%), IHF (2/141, 1%) or NBD (7/270, 2.5%). The frequency of 
AIDA was higher (3/38, 8%, p=0.006) in ARVC probands, AR (8/37, 21.6%, p=0.00001) and in 
HR (14/96, 14.6%, p=0.00001) than in NICD (6/160, 3.75%), IHF (3/141, 2%) or NBD (1/270, 
0.37%).  The frequency of AHA was similar in probands (14/38, 36.8%), AR (14/37, 37.8%,) 
and in HR (24/96, 25%) (p=NS). Similarly, the frequency of AIDA did not differ in probands 
(3/38, 8%), AR (8/37, 21.6%) and in HR (14/96,14.6%) (p=NS).   
Associations of AHA and AIDA status with clinical and diagnostic features are shown in 
Table 2. AHA positive status was associated with higher frequency of palpitation (p=0.004), ICD 
implantation for primary prevention of sudden cardiac death (p=0.021), greater left ventricular 
(LV) septal (p=0.004) and posterior wall end-diastolic thickness (p=0.004), lower LV ejection 
fraction (p=0.004) and tended to be associated with chest pain (p=0.08).  AIDA positive status 
was associated with both lower RV and LV echocardiographic ejection fraction (p=0.027 and 
p=0.027 respectively). AHA and/or AIDA positive status in the proband and/or at least one of 
the respective relatives was more common in familial (17/20, 85%) than in sporadic (10/22, 
45%) pedigrees (p=0.007). 
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Frequency of mutations in ARVC genes and associations with clinical, diagnostic features 
and autoantibody status. 
Classification of the detected desmosome variants by ACMG criteria identified 8 pathogenic 
loss-of-function (nonsense and frameshift) variants in 8 probands of the 38 tested (21%), 4 
variants of unknown significance and 12 benign/likely benign variants (Table 3). The degree of 
relatedness of relatives in gene-elusive families was similar to that of gene-positive relatives 
(first degree 55/71, 77% vs 25/30, 83% respectively, p=NS).  Pathogenic gene mutations were 
present in similar proportions of probands (8/38, 21%), AR (6/25, 24%) and HR (9/76, 11.8%) 
(p=NS). The most common mutated gene was PKP2, with relative frequencies of 5 (13%) 
probands, 4 (16%) AR and 6 (8%) of HR respectively (p=NS); the second most common gene 
was DSP, with relative frequencies of 2 (5 %) probands, 2 (8%) AR and 2 (3%) of HR 
respectively (p=NS). Pathogenic DSG2 mutations had relative frequencies of 1 (2.6%) of 
probands, 0 (0%) AR and 2 (2.6%) of HR respectively (p=NS); no DSC2 or JUP pathogenic 
mutations were found.  
Significant associations of pathogenic mutations with clinical, diagnostic features and 
with autoantibody status in probands and relatives are shown in Table 4. Overall, individuals 
with any pathogenic mutation as compared to those without had a larger RV end-diastolic 
volume (p=0.02), a higher frequency of negative t waves in leads V1-V3 (p=0.002), and tended 
to have higher frequency of ICD (p=0.09).  PKP2 mutation positive, as compared with PKP2 
negative patients, had a higher frequency of ICD implants for primary or secondary prevention 
(p=0.01), larger RV dimensions (p=0.004). DSP positive mutations were associated with larger 
RV outflow tract dimensions (p=0.004) and longer QRS duration (p=0.005). DSG-2 mutations 
did not show significant associations.  Excluding probands, AHA and of AIDA rates were 
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similar in gene-positive (carriers) relatives, gene-negative (NOT carriers) relatives from gene-
positive families, and gene-elusive (or not gene-tested) relatives. Conversely, each of the 3 
subgroups of relatives had significantly higher frequencies of inflammatory markers compared to 
individuals from control groups (NBD, IHF and NICD) (Suppl. Tables 1 and 2).  
 
Discussion 
Significance and specificity of AHA and AIDA in ARVC families 
In this study organ-specific AHA were found in 37% of affected ARVC patients and in 25% of 
HR, AIDA in 15% of affected patients and HR. In addition AHA and/or AIDA positive status in 
probands and/or in their relatives was present in the majority (85%) of familial and in 45% of 
sporadic ARVC pedigrees. Conversely, these antibodies were absent or uncommon in a large 
number of NICD (including 67 patients with another specific genetically determined 
cardiomyopathy, hypertrophic cardiomyopathy), ischemic heart disease and normal control 
individuals.  
The IF technique used on human myocardium and skeletal muscle is standardized, 
validated and able to distinguish organ-specific cardiac from partially organ-specific (cross-
reactive 1 pattern) or fully skeletal muscle cross-reactive AHA (cross-reactive 2 pattern) 21. Each 
assay includes controls for non-specific antibody binding21. The organ-specific vs cross-reactive 
AHA patterns have previously been confirmed by absorption studies on heart, skeletal muscle, 
and liver as control21, therefore IF per se on human substrate is able to distinguish cardiac-
specific from skeletal muscle cross-reactive AHA. Recognized autoantigens for AHA are alpha 
(entirely cardiac-specific isoform) and beta myosin heavy chain (partially cross-reactive with 
skeletal muscle) and other unidentified autoantigens by Western blot32. The AIDA pattern is 
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organ-specific; the intercalated disks are specialized cardiac structures, no AIDA binding is 
present on skeletal muscle20. 
The higher frequency of AHA and AIDA in ARVC probands and relatives than in 
controls is in keeping with autoimmune involvement in ARVC, as previously seen in 
autoimmune myocarditis/dilated cardiomyopathy and in other organ-specific autoimmune 
diseases, such as type 1 insulin-dependent diabetes mellitus (IDDM).16-21 The findings of this 
study are also in keeping with a recent report of anti-DSG-2 antibodies in 45 index ARVC 
patients.22 A unique finding of the present study is that, for the first time, AHA and/or AIDA 
were found in HR (e.g. symptom-free, with normal ECG and echocardiogram). In autoimmune 
diseases apparently healthy relatives are potentially at risk of disease development, particularly if 
they are autoantibody positive. Autoimmune diseases result from both genetic and environmental 
triggers. 17,19 In autoimmune dilated cardiomyopathy AHA are found years before disease 
development and identify family members at risk.17,19 Although the same may apply to ARVC, 
this is a cross-sectional study; longitudinal prospective studies are warranted to prove the 
possible role of AHA and AIDA as early predictors of disease development in antibody-positive 
unaffected ARVC relatives with or without a pathogenic mutation. The trend towards a lower 
frequency of AIDA in probands as compared to AR and HR may be related to older age and 
long-standing disease in probands, with reduction of antibody titres with disease progression, 
similar to what is seen in autoimmune dilated cardiomyopathy and in IDDM.17,18  
AHA, AIDA status and genetic background. 
In this study, AHA and/or AIDA were found in similar proportions of patients and relatives with 
and without pathogenic mutations.  Similarly, in another study the anti-DSG2 antibodies were 
present regardless of the underlying mutation 22. This may relate, in both studies, to the small 
 
D
ow
nloaded from
 http://ahajournals.org by on A
pril 3, 2020
10.1161/CIRCULATIONAHA.119.043931 
13 
number of mutations in single genes and subsequently a reduced statistical power to detect 
associations. Any association between an antibody type and specific gene mutations warrants 
confirmation on larger numbers.  The finding of genotype negative, antibody positive pedigrees 
may suggest that a subset of ARVC cases are non-genetic and entirely caused by autoimmune 
disease, or that new disease genes are yet to be discovered. Currently, the genetic cause of 
ARVC is still elusive in about 50% of index cases.1,3–6,11,23,24,26 However, this is the first family 
study to show that autoimmunity seems to be involved in the majority of familial ARVC (85%) 
and in 45% of sporadic ARVC pedigrees, similar to what is found with the same autoantibody 
markers, AHA, in autoimmune dilated cardiomyopathy. 17 
ARVC and myocarditis: autoimmunity as a common pathogenetic link  
Autoimmune involvement in ARVC is in keeping with the pathological description of virus-
negative myocarditis in up to 70% of  biopsy or autopsy tissue in ARVC12–14; in addition, the 
“hot phases” of ARVC are clinically indistinguishable from the pseudo-infarct presentation of 
myocarditis14. Therefore, the immunological findings shown here may provide the missing link 
for these observations. In other autoimmune diseases, the presence of specific autoantibody 
markers is associated and predicts “hot phases”, or disease relapses.16-21  
In keeping with other autoimmune diseases18, in the present study AHA and/or of AIDA 
were associated with clinical findings of disease activity or severity (chest pain, palpitation,  
lower left and/or right ventricular ejection fraction, and ICD implantation) in ARVC probands 
and AR.  The anti-DSG-2 antibodies reported by others were also associated with a higher 
frequency of ventricular ectopic beats22.  
The data provided here suggest novel insights into ARVC pathogenesis. So far, 
myocarditis has been considered by clinicians as a differential diagnosis from ARVC or a non-
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specific phenomenon secondary to tissue injury in a genetically-determined cardiomyopathy. 
However, in another heart muscle disease, hypertrophic cardiomyopathy, where there is no 
myocardial inflammation at histopathological analysis, AHA or AIDA frequencies were not 
increased21 and others did not find anti-DSG2 antibodies22.   Conversely, in this study AHA and 
AIDA and, in another study, anti-DSG2 antibodies 22 were associated with ARVC, in keeping 
with the proposal made here and by others22 that autoimmunity to myosin (one of the 
autoantigens recognised by AHA by western blotting)32 and to intercalated disk components 
(recognised by AIDA and the anti-DSG2 antibodies22) is involved in ARVC pathogenesis.  
Polyclonal humoral reactivity in ARVC 
In the present IF study AIDA were identified in a subset of ARVC probands and AR, conversely 
others, using western blot and ELISA, found anti-DSG2 antibodies in almost all index ARVC 
individuals22.  The discrepancy may relate to different sensitivity of the immunological 
techniques and/or heterogeneity of patients. In previous work on AHA it was showed that 
western blot32 and ELISA16 are more sensitive than IF in recognizing autoantibodies directed 
against specific heart autoantigens, which for AHA, include alpha and beta myosin heavy chain 
isoforms32. On the other hand, IF, the standard autoimmune serology technique, is best suited for 
the detection of multiple autoantibody reactions simultaneously 18,21, particularly in a newly 
suspected organ-specific autoimmune disease, such as ARVC, on a sizable number of patients, 
relatives and controls.  The present IF findings show, as in other organ-specific autoimmune 
diseases, a polyclonal humoral autoimmune reactivity in ARVC sera including AHA (which are 
directed against alpha and beta myosin heavy chains and other yet unidentified autoantigens32) 
and AIDA (directed against yet unknown autoantigens). Since this study tested more ARVC 
patient and relative cohorts than others22, it is likely that a greater heterogeneity of both genetic 
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backgrounds and autoantibody responses was present. It remains to be seen whether or not 
patients who are anti-DSG-2 antibody positive are also AHA and AIDA positive, or whether 
distinct patient subsets produce anti-DSG2 antibodies22 or AHA and AIDA. To this end 
collaborative work among laboratories which are testing distinct antibodies will be of great 
interest.  
Regarding the AHA, identified autoantigens include alpha and beta myosin heavy 
chain32, which represents the most abundant heart proteins. Although in ARVC the genetically-
defective cardiomyocyte structures are thought to be predominantly the intercalated disks, it is 
quite conceivable that, following myocyte cell damage related to these specialised structures, the 
whole cell becomes dysfunctional or dies, leading to release of myosin, as well as other 
autoantigens, and stimulating the immune system to AHA production33, as well as AIDA and 
anti-DSG2 antibodies22.  
Future clinical perspectives 
AHA and AIDA detected by indirect IF represent recognized organ-specific and disease-specific 
markers in ARVC, in keeping with Rose-Witebsky criteria18, thus in ARVC one major criteria 
for organ-specific autoimmunity is met.  However, at least two major Rose-Witebsky criteria 
should be fulfilled to classify a new disease entity as autoimmune18.  More work is needed, 
particularly in early genetically confirmed ARVC and in clinically “hot phases”, to detect 
potential involvement of cell-mediated autoimmunity, and to clarify immune features in situ, 
such as quantity and phenotype of inflammatory myocardial infiltrates and potential expression 
of Human Leucocyte Antigens (HLA) on EMB16,18,33. Another clinical research direction is the 
potential use of immunosuppression in biopsy-proven virus-negative autoantibody-positive 
inflammatory ARVC. Response to immunosuppression is a major criterion for an autoimmune 
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disease and is therefore the standard therapy in organ-specific and systemic autoimmune 
disorders.16,18 Similarly, it is becoming of standard use in biopsy-proven virus-negative 
myocarditis/ inflammatory dilated cardiomyopathy.16,17,19 In ARVC there is no aetiology-
directed therapy to stop or slow down disease progression.  Therefore 
immunosuppression/immunomodulation, with its current wide range of drugs and interventions, 
may be a promising new clinical perspective. Response to immunosuppression, to be tested by an 
appropriate controlled trial design, would also provide a second fulfilled major Rose-Witebsky 
criteria to classify ARVC as autoimmune.18 
Study limitations 
A first limitation of this study is deriving from being a cross-sectional study, and caution should 
be taken in inferring causality; this study is unable to determine whether auto-immunity is 
primary/causative or is secondary to the primary ARVD process.  A second limitation is that 
only a small subset of patients, 26 out of a total of 78 (including probands and affected relatives) 
underwent EMB, thus it is not feasible to relate the presence of AHA or AIDA with the 
histological confirmation of virus-negative myocardial inflammation. In the present study 
myocarditis was not found in biopsy-proven patients; this may reflect EMB sampling error, 
and/or the fact that EMB, an invasive procedure, was performed late in the disease stage, and in 
those patients who did not reach Task Force criteria at the end of non-invasive diagnostic work-
up. Nonetheless, since all study patients fulfilled 2010 revised Task force criteria, including 
genetic characterisation3, we think that they are truly representative of typical ARVC.  
Work is in progress to identify the specific autoantigenic targets in AIDA, although this was 
beyond the study aims.  By passive transfer experiments, it has been previously reported that 
AHA purified from dilated cardiomyopathy and myocarditis sera may be directly pathogenic.34   
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However, this has not yet been shown for AHA or AIDA purified from ARVC patients, 
therefore, although in this study AHA and AIDA were associated with clinical features of 
disease activity or severity in ARVC, this does not imply that they are directly pathogenic22. 
Future work is needed to clarify this issue.  
The present study focused on the main cause of ARVC, the desmosomal genes; the 
majority of patients with an identified pathogenic variant have a mutation in one of these five 
genes. Desmosomal gene mutations are typically associated with a classic form of ARVC as it is 
extensively described in the literature23-24,35. Mutations in other genes associated with ARVC 
account for a very small percentage of cases23-24. Other, non-desmosomal, genes have been 
reported to be responsible for other forms of the disease (recently collectively termed 
arrhythmogenic cardiomyopathy) which are phenotypically distinct35. For example, the 
phenotypes associated with mutations in phospholamban, desmin and lamin are characterised by 
increased risk of life-threatening arrhythmia, myocardial structural abnormalities, usually 
predominantly of the left ventricle and differ from the classic ARVC phenotype35.  
In addition, to date there have been no reports linking non-desmosomal genes with autoimmunity 
and ARVC. The only report of autoimmunity in ARVC concerned antibodies against 
desmoglein-2 which is a desmosomal protein22. 
Conclusions 
Presence of AHA and AIDA provides evidence of autoimmunity in the majority (85%) of 
familial and in 45% of sporadic ARVC. Although in probands and in affected relatives these 
antibodies were associated with disease severity features, longitudinal studies are needed to 
clarify whether they may predict ARVC development in healthy relatives. 
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Table 1. Clinical and diagnostic baseline features in ARVC 
 
 Probands (n=42) AR (n=37) HR (n=96) P 
Age, median (IQR) 41 (33;49) 35 (18;46) 27 (17;45) ns 
Female sex 18 (43%) 14 (38%) 47 (49%) Ns 
NYHA class: 
I  
II 
III or IV  
 
26 (62%) 
13 (31%) 
3 (7%) 
 
34 (92%) 
3 (8%) 
0 (0%) 
 
87 (91%) 
8 (8%) 
1 (1%) 
0.007 
Chest Pain 8 (19%) 6 (16%) 6 (6%) ns 
Palpitations 32 (76%) 7 (19%) 16 (19%) 0.007 
Syncope 10 (24%) 4 (11%) 1 (1%) 0.007 
Symptoms at follow-up 29 (69%) 5 (13%)  3 (3%) 0.007 
ICD 11 (26%) 1 (2.7%) 0 (0%) 0.007 
Family history of AID 16 (38%) 15 (40.5%) 20 (21%) ns 
EMB:  
Not done 
Diagnostic 
Non diagnostic 
 
19 (45%) 
18 (43%) 
5 (12%) 
  
34 (92%) 
2 (5%) 
1 (3%) 
 
96 (100%) 
0 (0%) 
0 (0%) 
0.007 
Rhythm: 
Sinus rhythm 
Atrial Fibrillation 
Pacemaker 
 
39 (93%) 
2 (5%) 
1 (2) 
 
37 (100%) 
0 (0%) 
0 (0%) 
 
96 (100%) 
0 (0%) 
0 (0%) 
ns 
VEs/24h , median (IQR) 5724 (800;165000) 37 (2,75;582) 1 (0;172) ns 
Couplets/24h, median (IQR) 149 (5,5;290) 1,5 (1;17,5) 0 0.013 
NSVT, n (%) 11 (26%) 1 (3%) 0 (0%) 0.064 
RV enddiastolic area, median (IQR) 20 (14;32) 16 (14;21) 15 (12;19) 0.007 
RV FAC, median (IQR) 45 (32;52) 47 (35;57) 55 (47;60) 0.007 
RV EDV/BSA, median (IQR) 27 (16;38) 18 (14;25) 16 (13;22) 0.007 
%RVEF, median (IQR) 50 (44;60) 56 (48;64) 61 (56;68) 0.007 
LV enddiastolic diameter, median (IQR) 50 (46;55) 48 (42;51) 45 (41;49) 0.007 
%FS, median (IQR) 33 (29;37) 38 (33;45) 38 (32;43) ns 
2-D echo LV EDV/BSA, median (IQR) 45 (41;55) 44 (35;49) 42 (36;50) 0.007 
2-D echo LVEF, median (IQR) 58 (49;63) 64 (56;68) 63 (60;69) 0.007 
Revised  major (>) and minor (<) 2010 Task force criteria: 
I. Global or regional dysfunction and structural alterations by 2-D echo, n (%): 
>  18 (43%) 13 (35%) 4 (4%) 0.007 
< 8(19%) 7 (19%) 1 (1%) 0.007 
III. repolarization abnormalities, n (%): 
>negative T wave in V1-V3 20 (48%) 9 (24%) 4 (4%) 0.007 
<negative T wave in V1-V2, no RBBB, 
aged above 14 yrs 
31 (74%) 17 (46%) 8 (8%) 0.007 
<negative T wave in V4  15 (36%) 7 (19%) 1 (1%) 0.007 
<negative T wave in V5  11 (26%) 0 (0%) 1 (1%) 0.007 
<negative T wave in V6  9 (21%) 0 (0%) 1 (1%) 0.007 
IV. depolarization/conduction abnormalities, n (%): 
> Epsilon wave in V1-V3 6 (14%) 2 (5%) 0 (0%) 0.007 
V. Arrhythmias, n (%) 
< VT 11 (26%) 1 (3%) 0 (0%) 0.064 
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< VEs 24 (57%) 3 (8%) 1 (1%) 0.007 
VI. Family history, n (%): 
<sudden death (age less than 35 yrs) due to 
suspected ARVC 
6 (14%) 11 (30%) 7 (7%) 0.013 
P-values are for overall comparison among probands, AR and HR, each row refers to a different variable 
(see statistics section for details on type of test used). Abbreviations: AID, autoimmune disease; AR, 
affected relatives; ARVC, arrhythmogenic right ventricular cardiomyopathy; BSA, body surface area; 2-
D echo, 2 dimensional echocardiography; EF, ejection fraction; EDV, endiastolic volume; EMB, 
endomyocardial biopsy; FAC, fractional area change; %FS, %fractional shortening; HR, healthy relatives; 
ICD, implantable cardioverter defibrillator; IQR, interquartile range, 25% and 75% ; LV, left ventricular; 
NYHA, New York Heart Association; VEs, ventricular ectopic beats; NSVT, nonsustained ventricular 
tachycardia; VT, ventricular tachycardia; RV, right ventricular. 
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Table 2. AHA and AIDA Status: Association with Clinical and Diagnostic Features  
 
 AHA positive (n=52) AHA negative (n=119) P 
Chest Pain 10 (19.2%) 10 (8.4%) 0.080 
Palpitations 22 (42.3%) 30 (25.2%) 0.004 
Persistent symptoms 16 (31%) 19 (16%) ns 
ICD 7 (13.5%) 4 (3.4%) 0.021 
LV enddiastolic diameter, median, median (IQR) 48 (44;52) 46 (41:51) 0.004 
LV interventricular enddiastolic septum thickness, 
median (IQR) 
10 (9;11) 9 (8;10) 0.004 
LV posterior wall enddiastolic thickness, median 
(IQR) 
9 (7;10) 8 (7;9) 0.004 
2-D echo LVEF, median (IQR) 60 (53;67) 63 (57;69) 0.004 
 AIDA positive (n=25) AIDA negative (n=146) P 
Dyspnea 7 (28%) 9 (6.2%) ns 
2-D echo RVEF , median (IQR) 54 (44; 60) 60 (54;67) 0.027 
2-D echo LVEF, median (IQR) 60 (53;65) 63 (57;68) 0.027 
Abbreviations: AHA= Anti-heart autoantibodies; AIDA= anti-intercalated disk autoantibodies; 2-D echo= 2 
dimensional echocardiography; EF, ejection fraction; ICD=implantable cardioverter defibrillator; IQR= interquartile 
range, 25% and 75% ; LV= left ventricular; RV= right ventricular. 
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Table 3. List of genetic variants. 
 
ARVC 
index case 
Gene Variant MAF in 
gnomAD  
ARVD/C Genetic Variants 
Database classification 
ACMG 
classification 
IT2 DSC2 c.1914G>C; p.Gln638His 0.0005 VUS Likely benign 
 PKP2 c.1592T>G; p.Ile531Ser 0.0048 No known pathogenicity Likely benign 
IT5 PKP2 c.2443_2448delAACACCinsGAAA; 
p.Asn815GlufsX11 
Not present Not present Pathogenic (Ia) 
IT7 PKP2 c.1216delG; p.Val406PhefsX14 Not present Not present Pathogenic (Ia) 
IT10 DSC2 c.2686_2687dupGA; p.Ala897LysfsX4 0.0086 No known pathogenicity VUS 
 DSG2 c.1038_1040delGAA; p.Lys346del 8.137e-6 Pathogenic Pathogenic (Ia) 
IT11 PKP2 c.76G>A; p.Asp26Asn 0.0079 No known pathogenicity Likely benign 
 PKP2 c.1799delA; p.Asp600ValfsX56 Not present Pathogenic Pathogenic (Ia) 
IT12 DSP c.2684A>G; p.Tyr895Cys 0.00014 Not present VUS 
IT13 PKP2 c.2009delC; p.Asn670ThrfsX14 Not present Pathogenic Pathogenic (Ia) 
IT17 JUP c.1942G>A; p.Val648Ile 0.0074 VUS Benign 
IT18 DSG2 c.2759T>G; p.Val920Gly 0.0035 VUS Benign 
 PKP2 c.1045A>G; p.Met349Val 6.61e-5 Not present Likely benign 
IT19 DSG2 c.2434G>A; p.Gly812Ser 3.60e-5 Pathogenic VUS 
IT20 JUP c.1807G>A; p.V603M 1.24e-5 Not present VUS 
IT21 DSP c.5851C>T; p.Arg1951X Not present Not present Pathogenic (Ia) 
IT23 PKP2 c.76G>A; p.Asp26Asn 0.0079 No known pathogenicity Likely benign 
IT27 PKP2 c.1759G>A; p.Val587Ile 0.0024 VUS Likely benign 
IT33 PKP2 c.209G>T; p.Ser70Ile 0.2081 No known pathogenicity Likely benign 
IT34 PKP2 c.1216delG; p.Val406PhefsX14 Novel N/A Pathogenic (Ia) 
 DSP c.3923G>C; p.Arg1308Pro 8.147e-5 Not present Likely benign 
IT35 DSP c.5498A>T; p.Glu1833Val 0.0096 VUS Benign 
IT36 DSP c.6208G>A; p.Asp2070Asn 0.0039 No known pathogenicity Benign 
IT37 DSP c.1465G>T; p.Glu489X Not present Not present Pathogenic (Ia) 
Abbreviations: ACMG= American College of Medical Genetics; ARVC= Arrhythmogenic right ventricular cardiomyopathy; 
ARVD= Arrhythmogenic right ventricular dysplasia; Genome Aggregation Database=gnomAD; MAF=minor allele frequency; 
N/A= not available; desmocollin-2 (DSC2), desmoglein (DSG2); desmoplakin (DSP) and plakoglobin (JUP); plakophilin-2 
(PKP2); VUS=variant of unknown significance. 
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Table 4. Pathogenic Mutations: Associations with Clinical, Diagnostic and Immune Features  
 
 Any mutation pos 
(n=23) 
Any mutation neg 
(n=116) 
p 
ICD 6 (26%) 6 (5%) 0.095 
Revised major III (neg T in V1-V3) 11 (48%) 19 (16%) 0.002 
RV end-diastolic area, cm2, mean (SD)  23 (10)  18 (6) 0.02 
RV EDV/BSA, ml/m2 mean (SD) 29 (15)  21 (10) 0.02 
AHA* 10 (45%) 30 (26%) ns 
AIDA* 3 (14%) 22 (19%) 0.099 
AHA and/or AIDA* 11 (50%) 40 (35%) ns 
 DSP pos (n=6) DSP neg (n=133) p 
QRS duration, msec,mean (SD) 100 (16) 88 (12) 0.005 
Rev <criteria (negative T V1-V4) 1 (17%) 1 (0.7%) ns 
RV outflow tract 1/BSA, mm, mean (SD) 20 (5) 15(3) 0.004 
RV outflow tract 4/BSA, mm, mean (SD) 22 (5) 16(3) 0.004 
AHA* 2 (33%) 38 (29%) ns 
AIDA* 1 (17%) 24 (18%) ns 
AHA and/or AIDA* 2 (33%) 49 (36%) ns 
 PKP-2 pos (n=15) PKP-2neg  (n=124) p 
ICD 5 (26%) 9 (8%) 0.011 
Syncope  6 (31%) 6 (5%) ns 
RV end-diastolic area, cm2, mean (SD)  24 (9)  18 (7) 0.004 
RV EDV/BSA, ml/m2, mean (SD) 31 (16)  21 (10) 0.004 
AHA* 0 (0%) 40 (30%) ns 
AIDA* 2 (14%) 23 (19%) ns 
AHA and/or AIDA* 9 (64%) 42 (34%) ns 
 DSG-2 pos (n=3) DSG-2 neg (n=136) p 
AHA* 0 (0%) 40 (30%) 0.060 
AIDA* 0 (0%) 25 (19%) ns 
AHA and/or AIDA* 0 (0%) 51 (39%) 0.060 
Abbreviations: BSA, body surface area; neg, negative; pos, positive; see Table 1-3 for remaining 
abbreviations. 
*Total for antibody tests: n=136; †No other significant associations were found for DSC2 mutations. 
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Figure Legends 
Figure 1. Study flow-chart 
Abbreviations: AHA= Anti-heart auto-antibodies; AIDA= anti-intercalated disk autoantibodies. 
Figure 2. Anti-heart auto-antibodies (AHA) and anti-intercalated disk autoantibodies 
(AIDA) patterns by indirect immunofluorescence test 
Negative AHA control serum pattern: panel A on human heart tissue: negative (x200), and panel 
B on human skeletal muscle: negative (x400). 
Organ-specific AHA pattern: panel C on human heart tissue: strong cytoplasmic and striational 
staining of cardiac myocytes (organ-specific AHA pattern); panel D (x400) on human skeletal 
muscle tissue: negative. 
Organ-specific AHA and AIDA pattern: panel E strong linear staining of the intercalated disks 
(AIDA pattern) and associated weak diffuse cytoplasmic organ-specific AHA pattern (x400);  
panel F (x400) on human skeletal muscle tissue: negative. 
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